Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia
This accredited symposium " Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertia" was held during the virtual EASD 2021 and consists of three educational videos.
Episodes 1-4 of 4
- Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertiaIntroduction on tackling cardiorenal risk in diabetes
Prof. Melanie Davies, MD
- Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertiaDialogue on how to overcome clinical inertia with regard to SGLT2i
Prof. Melanie Davies, MD
Prof. Nikolaus Marx, MD
- Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertiaSGLT2i: Overview of recent trials and guideline recommendations
Prof. Nikolaus Marx, MD
- Teaming up to tackle cardiorenal risk in diabetes - Role of SGLT2i: How to overcome clinical inertiaSymposium on the role of SGLT2i in tackling cardiorenal risk in diabetes
Prof. Melanie Davies, MD
Prof. Nikolaus Marx, MD